Levee Medical Advances Pivotal Trial Enrollment for Voro Urologic Scaffold

A LinkedIn post from Levee Medical highlights that UChicago Medicine and Dr. Abhinav Sidana have enrolled their first patient in the ARID II IDE pivotal trial. The site is described as the 15th location to enroll a patient, marking further progress in patient recruitment for the study of Levee Medical’s Voro urologic scaffold.

According to the post, the ARID II trial is focused on evaluating the Voro device’s impact on early and long-term continence outcomes following prostate surgery. For investors, continued site activation and enrollment momentum may indicate advancing clinical validation, a key de-risking step for a device targeting post-prostatectomy care and potential future commercialization.

The post also underscores collaboration with a major academic medical center, which could support clinical credibility if trial results are favorable. While no financial metrics or timelines are mentioned, successful progression of the pivotal trial may influence Levee Medical’s regulatory pathway, reimbursement prospects, and eventual market positioning in urologic surgery support technologies.